5 stories
The FLOW trial showed semaglutide reduced major kidney disease events by ~24%, while the SELECT trial found a 20% reduction in major adverse cardiovascular events among 17,600+ adults.
A study of ~175,000 Type 1 diabetes patients found GLP-1 receptor agonists reduced five-year cardiovascular event risk by 15% and end-stage kidney disease by 19%, with no increase in severe hypoglycemia. Published in Nature Medicine.
Under new UK guidance, GPs can prescribe semaglutide (Wegovy) to overweight patients who have had heart attacks, strokes, or serious circulation problems, expanding its use beyond weight management.
A condition-by-condition guide examining what's proven, promising, and untested for GLP-1 drugs beyond weight loss — covering cardiovascular disease, addiction, kidney disease, and neurological conditions.
The European Medicines Agency formally approved semaglutide with cardiovascular and stroke-related benefits — a first for any GLP-1 receptor agonist in Europe.